Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Cancer Chemother Pharmacol

Search In Journal Title:

Abbravation: Cancer Chemotherapy and Pharmacology

Search In Journal Abbravation:

Publisher

Springer Berlin Heidelberg

Search In Publisher:

DOI

10.1016/1381-1169(95)00230-8

Search In DOI:

ISSN

1432-0843

Search In ISSN:
Search In Title Of Papers:

Elevated circulating monocyte chemoattractant prot

Authors: Faruk Tas Senem Karabulut Murat Serilmez Mehmet Karabulut Derya Duranyildiz
Publish Date: 2015/10/23
Volume: 77, Issue: 1, Pages: 127-131
PDF Link

Abstract

Monocyte chemoattractant protein 1 MCP1/CCL2 is a member of the CC chemokine family and a potent chemotactic factor for monocytes that regulate migration and infiltration of monocytes and macrophages It plays an important role in the pathogenesis of multiple malignancies and its expression strongly also affects the outcomes of cancer patients The objective of this study was to determine the clinical significance of the serum levels of MCP1/CCL2 in gastric cancer patientsThe median age at diagnosis was 60 years range 21–84 years The baseline serum MCP1/CCL2 concentrations of the gastric cancer patients were significantly higher than of healthy subjects p  0001 The known clinical variables including gender age site of lesion histopathology tumor size lymph node involvement and stage of disease were not found to be correlated with serum MCP1/CCL2 concentrations p  005 However a significant relationship was shown between serum MCP1/CCL2 levels and response to chemotherapy p = 005 Chemotherapy nonresponsive patients had higher serum MCP1/CCL2 concentrations Serum MCP1/CCL2 concentrations were not associated with prognosis on both progressionfree and overall survival p = 053 and p = 039 respectivelyElevated circulating MCP1/CCL2 level may be an unfavorable predictive factor to chemotherapy based on platinum and taxane in patients with gastric cancer However serum MCP1/CCL2 concentrations were not associated with prognosis on both progressionfree and overall survival

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer
  2. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
  3. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab
  4. Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages
  5. Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia
  6. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice
  7. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer
  8. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
  9. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy- d -glucose in tumor cells treated under hypoxic vs aerobic conditions
  10. Anticancer effect of ( E )-2-hydroxy-3′,4,5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization
  11. CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil
  12. A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
  13. Clindamycin–paclitaxel pharmacokinetic interaction in ovarian cancer patients
  14. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
  15. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo
  16. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model
  17. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib
  18. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies
  19. Hypericin—an inhibitor of proteasome function
  20. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis
  21. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
  22. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
  23. HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells
  24. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma
  25. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma
  26. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin
  27. Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives
  28. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
  29. Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients
  30. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
  31. A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer
  32. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice
  33. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
  34. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
  35. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
  36. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer
  37. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
  38. Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells
  39. Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats
  40. Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression
  41. The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines
  42. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
  43. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase
  44. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma
  45. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors
  46. The relative bioavailability of gefitinib administered by granular formulation
  47. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors
  48. Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy
  49. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling
  50. Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy
  51. Phase II study of rubitecan in recurrent or metastatic head and neck cancer
  52. Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer
  53. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan
  54. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
  55. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency
  56. Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma
  57. A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas
  58. Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line
  59. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer
  60. Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis
  61. Defining clinically relevant molecular subsets of lung cancer
  62. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
  63. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies
  64. A late phase II study of S-1 for metastatic pancreatic cancer
Search Result: